# Ocugen, Inc. (OCGN) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_290571cc2b5097e4a78b · retrieved 2026-08-12T07:01:00.703Z

## Overview
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases, with a modifier gene therapy platform targeting inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy.

Ocugen, Inc. closed an offering of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, including the full exercise of a $15.0 million over-allotment option, for net proceeds of approximately $112.5 million. Approximately $32.7 million of net proceeds was used to fully retire the Avenue Capital loan, eliminating 12.25% interest-rate debt from the Company's capital structure. The offering extends Ocugen's cash runway into 2028.

## Terms
- Deal value: $130.0M · Consideration: cash

## Key dates
- Announced 2026-08-06

## Timeline
- 2026-08-06 · 8-K (0001104659-26-091691): 8-K - Ocugen, Inc. — *Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases, with a modifier gene therapy platform targeting inherited retinal diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy.* Ocugen, Inc. closed an offering of $130.0 million aggregate principal amount of 6.75% Convertible Senior Notes due 2034, including the full exercise of a $15.0 million over-allotment option, for net proceeds of approximately $112.5 million. Approximately $32.7 million of net proceeds was used to fully retire the Avenue Capital loan, eliminating 12.25% interest-rate debt from the Company's capital structure. The offering extends Ocugen's cash runway into 2028.
  https://www.sec.gov/Archives/edgar/data/1372299/0001104659-26-091691.txt

## Citations
- 0001104659-26-091691 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926091691